Atypical E2Fs inhibit tumor angiogenesis

B.G.M.W. Weijts; B. Westendorp; B. T. Hien; L. M. Martínez-López; H.M. van Zijp; I. Thurlings; R. E. Thomas; S. Schulte-Merker; W. J. Bakker; A. de Bruin

doi:10.1038/onc.2017.336

Atypical E2Fs inhibit tumor angiogenesis

B.G.M.W. Weijts, B. Westendorp, B. T. Hien, L. M. Martínez-López, H.M. van Zijp, I. Thurlings, R. E. Thomas, S. Schulte-Merker, W. J. Bakker^*, A. de Bruin^*

^*Corresponding author for this work

Cancer

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.

Original language	English
Pages (from-to)	271-276
Number of pages	6
Journal	Oncogene
Volume	37
Issue number	2
DOIs	https://doi.org/10.1038/onc.2017.336
Publication status	Published - 11 Jan 2018

Access to Document

10.1038/onc.2017.336Licence: CC BY

onc2017336Final published version, 1.48 MBLicence: CC BY

Cite this

@article{abad73ab5015477ba39fb408ea1fc972,

title = "Atypical E2Fs inhibit tumor angiogenesis",

abstract = "Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.",

author = "B.G.M.W. Weijts and B. Westendorp and Hien, {B. T.} and Mart{\'i}nez-L{\'o}pez, {L. M.} and {van Zijp}, H.M. and I. Thurlings and Thomas, {R. E.} and S. Schulte-Merker and Bakker, {W. J.} and {de Bruin}, A.",

note = "Funding Information: This study was financially supported by grants from the Dutch Cancer Society (UU2009–4353) to WJB, and (UU2013-5777) to BW and AdB. From the Association of International Cancer Research (09–0718) to WJB, and from the Netherlands Organization for Scientific Research (NWO-ALW 11-28) to AdB. Publisher Copyright: {\textcopyright} The Author(s) 2018.",

year = "2018",

month = jan,

day = "11",

doi = "10.1038/onc.2017.336",

language = "English",

volume = "37",

pages = "271--276",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Atypical E2Fs inhibit tumor angiogenesis

AU - Weijts, B.G.M.W.

AU - Westendorp, B.

AU - Hien, B. T.

AU - Martínez-López, L. M.

AU - van Zijp, H.M.

AU - Thurlings, I.

AU - Thomas, R. E.

AU - Schulte-Merker, S.

AU - Bakker, W. J.

AU - de Bruin, A.

N1 - Funding Information: This study was financially supported by grants from the Dutch Cancer Society (UU2009–4353) to WJB, and (UU2013-5777) to BW and AdB. From the Association of International Cancer Research (09–0718) to WJB, and from the Netherlands Organization for Scientific Research (NWO-ALW 11-28) to AdB. Publisher Copyright: © The Author(s) 2018.

PY - 2018/1/11

Y1 - 2018/1/11

N2 - Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.

AB - Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.

UR - http://www.scopus.com/inward/record.url?scp=85040525671&partnerID=8YFLogxK

U2 - 10.1038/onc.2017.336

DO - 10.1038/onc.2017.336

M3 - Article

AN - SCOPUS:85040525671

SN - 0950-9232

VL - 37

SP - 271

EP - 276

JO - Oncogene

JF - Oncogene

IS - 2

ER -

Atypical E2Fs inhibit tumor angiogenesis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this